Genexine CEO Neil Warma Resigns... Hong Seongjun to Lead as Sole CEO

Resignation Due to Personal Reasons
"Planning to Recruit a Competent Successor CEO"

Genexine announced on the 12th that following the resignation of CEO Neil Warma, the company will transition to a sole CEO system under Hong Seong-jun.

Nil Wurma, former CEO of Genexine, is being interviewed by Asia Economy. [Photo by Genexine]

CEO Neil Warma stated, "I have been working to globalize Genexine while traveling between the United States and Korea, but due to personal reasons, I am resigning and plan to be with my family in the United States."

Genexine announced that it plans to recruit a capable successor with expertise in the bio field to strengthen its professional management system. Hong Seong-jun, who will lead the company as the sole CEO, was newly appointed as Genexine's Chief Financial Officer in 2020 and was appointed as a co-CEO earlier this year.

CEO Hong said, "The most important thing right now is to maximize the value of our products. We are focusing on global new drug development and commercialization through our core pipelines while simultaneously striving to secure future growth engines. We will expand clinical trials beyond Asia to Europe and establish a systematic and transparent management system to leap forward as a global bio company."

CEO Hong continued, "We will continue efforts to reduce costs through a selection and concentration strategy while also continuously seeking opportunities for license-out and co-development partnerships with global pharmaceutical companies. We will do our best to achieve the fruits of new drug development as soon as possible and take responsibility as a leading K-bio company to ensure stable growth."

Genexine is currently awaiting the results of its application for marketing approval of 'GX-E4 (Epoetin Alpha),' a long-acting anemia treatment for non-dialysis chronic kidney disease patients, submitted to the Indonesian Food and Drug Authority. Additionally, the long-acting growth hormone 'GX-H9' is completing Phase 3 clinical trials in China and is preparing for priority launch in China within 1 to 2 years. The company is also accelerating the development of key pipelines such as the DNA therapeutic vaccine 'GX-188E' and the immuno-oncology drug 'GX-I7' in collaboration with global partners.